Ipca Laboratories Ltd. (NSE: IPCALAB, BSE: 524494) is a Mumbai, Maharashtra-based company in the Medicinal Chemicals and Botanical Products industry. With a market capitalisation of ₹49,556 Cr, it ranks #194 by market cap among the 6,189 Indian listed companies on FinBizNet, and #11 of 86 in Medicinal Chemicals and Botanical Products. At ₹1,953.30 (as of 26 Oct 2026), the share price is 4.2% below its 52-week high of ₹2,038.00 and 54.0% above its 52-week low of ₹1,268.00. The share price is up 50.6% over one year and up 10.8% over three months.
| Current Price | ₹1,953.30 |
|---|---|
| Market Cap | ₹49,556 Cr |
| NSE Symbol | IPCALAB |
| BSE Code | 524494 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products |
| P/E Ratio | 43.4 |
| Return on Equity | 13.22% |
| Return on Assets | 8.42% |
| 52-Week Range | ₹1,268.00 – ₹2,038.00 |
| 1-Year Price Change | +50.6% |
| 3-Month Price Change | +10.8% |
| Beta (1Y) | -0.05 |
| Dividend Yield | 0.31% |
| Headquarters | Mumbai, Maharashtra |
| Website | www.ipca.com |
| Revenue | ₹2,788 Cr |
|---|---|
| Net Profit | ₹423 Cr |
| Net Margin | 15.2% |
| EPS (Basic) | ₹15.84 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Ipca Laboratories Limited, an integrated pharmaceutical company, manufactures and markets formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India, Europe, Africa, the Americas, Asia, the Commonwealth of Independent States, and Australasia. The company offers APIs in anti-hypertensive, anti-malarial, diuretic, DMARD, anti-hypertensive, and anthelmintic therapeutic areas. It also provides generic and branded formulations in various therapeutic segments, including allergy, anti-neoplastic/cancer drugs, anti-arthritic, anti-epileptic, anti-hypertensive, cardiology, diabetes, dermatology, diabetology, emollients/protectives, fever, gastroenterology, helminthics, hepatoprotectives, immunosuppressant, infectious diseases, malaria, neurology, neuropathic pain, and NSAIDs, as well as nutraceuticals, ophthalmology, oral anti diabetes drug, orthopedics, probiotics, psychiatry, respiratory, rheumatology, and urology. The company also exports its products
1. Pharmaceuticals-This segment manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients for various therapeutic segments.
1. Pharmaceuticals-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4,19,404 Cr | 36.6 | 14.72% | ₹15,300 Cr | +5.4% |
| Zydus Lifesciences Ltd | ₹1,12,658 Cr | 22.5 | 18.32% | ₹8,017 Cr | +14.7% |
| Cipla Limited | ₹1,08,090 Cr | 27.9 | 11.74% | ₹7,119 Cr | -14.7% |
| Laurus Labs Ltd | ₹1,06,442 Cr | 119.8 | 17.74% | ₹2,026 Cr | +125.7% |
| Dr.Reddys Lab | ₹1,02,010 Cr | 23.8 | 11.52% | ₹8,698 Cr | -0.9% |
| Mankind Pharma | ₹91,379 Cr | 47.8 | 12.45% | ₹4,031 Cr | -9.9% |
| Aurobindo Pharma Ltd. | ₹90,432 Cr | 26 | 9.93% | ₹9,150 Cr | +41.7% |
| Lupin Ltd | ₹88,018 Cr | 16.5 | 26.91% | ₹8,277 Cr | -1.1% |
| Ipca Laboratories Ltd. | ₹49,556 Cr | 43.4 | 13.22% | ₹2,788 Cr | +50.6% |
Listed by market capitalisation. Ratios are shown for context only.
Ipca Laboratories Ltd. is trading at ₹1,953.30, with a market capitalisation of ₹49,556 Cr.
Ipca Laboratories Ltd. operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).
Ipca Laboratories Ltd. has a P/E of 43.4 and a return on equity of 13.22%.
Ipca Laboratories Ltd. is listed on the NSE under the symbol IPCALAB and on the BSE under the scrip code 524494.
Ipca Laboratories Ltd.'s share price is up 50.6% over one year and up 10.8% over three months. Its 52-week range is ₹1,268.00 to ₹2,038.00.
In Q1 FY27, Ipca Laboratories Ltd. reported revenue of ₹2,788 Cr and net profit of ₹423 Cr, with basic EPS of ₹15.84 (consolidated, parsed from the company's exchange filing).
Data as of 26 Oct 2026. Descriptive market data only — not investment advice.